The brim of uncertainty in adjuvant treatment of melanoma
Mené sur 498 patients atteints d'un mélanome présentant la mutation BRAF V600 et ayant subi une résection, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité du vémurafenib dispensé par voie orale en traitement adjuvant
Until recently, standard options for adjuvant melanoma therapy have been limited to interferon-
α and ipilimumab, both of which are associated with substantial toxicity and only modest clinical benefit.1
–3 2017 was a major year for the adjuvant treatment of melanoma as two new regimens were shown to significantly lower the risk of recurrence in patients with resected, high-risk melanoma. The anti-programmed death 1 agent, nivolumab (compared with ipilimumab in the Checkmate 238 study4) and the combination of the RAF and MEK inhibitors, dabrafenib and trametinib (compared with placebo in the COMBI-AD study5) were both shown to improve disease-free survival.
The Lancet Oncology , commentaire, 2017